Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients
Gespeichert in:
| Veröffentlicht in: | Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2020-03, Vol.20 (3), p.e137-e143 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e143 |
|---|---|
| container_issue | 3 |
| container_start_page | e137 |
| container_title | Clinical lymphoma, myeloma and leukemia |
| container_volume | 20 |
| creator | Chaulagain, Chakra P. Diacovo, Julia M. Elson, Leah Comenzo, Raymond L. Samaras, Christy Anwer, Faiz Khouri, Jack Landau, Heather Valent, Jason |
| description | |
| doi_str_mv | 10.1016/j.clml.2019.12.022 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8183688</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2152265020300070</els_id><sourcerecordid>32029395</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-efff9e68b38b5c94799798087d812d2b449561842c3688949f83e3381ffe93fb3</originalsourceid><addsrcrecordid>eNp9kNtKxDAURYMo3n_AB-kPtObSdhIQQcYriCM6Poc0PakZ0nZIOgP-vSmjg774lISz9zpkIXRGcEYwKS8WmXatyygmIiM0w5TuoENKCprSshS723uBD9BRCAuMJzhm99EBo5gKJopD1Nwor4ZVu2pVlVYqQJ28QmNb6BLbJXMParBdk0xd3ymXvDgVWpVMwbnkGfrl-Axj8K13tk5mvlFjSXUhjrohorRdWuiGcIL2jHIBTr_PY_R-dzufPqRPs_vH6fVTqnNKhxSMMQJKXjFeFVrkEyEmgmM-qTmhNa3yXBQl4TnVrORc5MJwBoxxYgwIZip2jK423OWqaqHWcbdXTi69bZX_lL2y8u-ksx-y6deSEz4iI4BuANr3IXgw2y7BctQuF3LULkftklAZtcfS-e-t28qP5xi43AQg_n1twcugoxcNtfWgB1n39j_-F7P_lZ0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Chaulagain, Chakra P. ; Diacovo, Julia M. ; Elson, Leah ; Comenzo, Raymond L. ; Samaras, Christy ; Anwer, Faiz ; Khouri, Jack ; Landau, Heather ; Valent, Jason</creator><creatorcontrib>Chaulagain, Chakra P. ; Diacovo, Julia M. ; Elson, Leah ; Comenzo, Raymond L. ; Samaras, Christy ; Anwer, Faiz ; Khouri, Jack ; Landau, Heather ; Valent, Jason</creatorcontrib><identifier>ISSN: 2152-2650</identifier><identifier>EISSN: 2152-2669</identifier><identifier>DOI: 10.1016/j.clml.2019.12.022</identifier><identifier>PMID: 32029395</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Amyloidosis ; Antibodies, Monoclonal - pharmacology ; Antibodies, Monoclonal - therapeutic use ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Daratumumab ; Humans ; Male ; Middle Aged ; Multiple myeloma ; Neoplasms, Plasma Cell - drug therapy ; Organ Transplantation - methods ; Plasmacytic post-transplant lymphoproliferative disorder ; Solid organ transplant ; Transplant Recipients - statistics & numerical data</subject><ispartof>Clinical lymphoma, myeloma and leukemia, 2020-03, Vol.20 (3), p.e137-e143</ispartof><rights>2020 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-efff9e68b38b5c94799798087d812d2b449561842c3688949f83e3381ffe93fb3</citedby><cites>FETCH-LOGICAL-c422t-efff9e68b38b5c94799798087d812d2b449561842c3688949f83e3381ffe93fb3</cites><orcidid>0000-0002-3152-1189 ; 0000-0002-4641-2217 ; 0000-0001-9169-3321</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2152265020300070$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32029395$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chaulagain, Chakra P.</creatorcontrib><creatorcontrib>Diacovo, Julia M.</creatorcontrib><creatorcontrib>Elson, Leah</creatorcontrib><creatorcontrib>Comenzo, Raymond L.</creatorcontrib><creatorcontrib>Samaras, Christy</creatorcontrib><creatorcontrib>Anwer, Faiz</creatorcontrib><creatorcontrib>Khouri, Jack</creatorcontrib><creatorcontrib>Landau, Heather</creatorcontrib><creatorcontrib>Valent, Jason</creatorcontrib><title>Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients</title><title>Clinical lymphoma, myeloma and leukemia</title><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><subject>Aged</subject><subject>Amyloidosis</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Daratumumab</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Neoplasms, Plasma Cell - drug therapy</subject><subject>Organ Transplantation - methods</subject><subject>Plasmacytic post-transplant lymphoproliferative disorder</subject><subject>Solid organ transplant</subject><subject>Transplant Recipients - statistics & numerical data</subject><issn>2152-2650</issn><issn>2152-2669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kNtKxDAURYMo3n_AB-kPtObSdhIQQcYriCM6Poc0PakZ0nZIOgP-vSmjg774lISz9zpkIXRGcEYwKS8WmXatyygmIiM0w5TuoENKCprSshS723uBD9BRCAuMJzhm99EBo5gKJopD1Nwor4ZVu2pVlVYqQJ28QmNb6BLbJXMParBdk0xd3ymXvDgVWpVMwbnkGfrl-Axj8K13tk5mvlFjSXUhjrohorRdWuiGcIL2jHIBTr_PY_R-dzufPqRPs_vH6fVTqnNKhxSMMQJKXjFeFVrkEyEmgmM-qTmhNa3yXBQl4TnVrORc5MJwBoxxYgwIZip2jK423OWqaqHWcbdXTi69bZX_lL2y8u-ksx-y6deSEz4iI4BuANr3IXgw2y7BctQuF3LULkftklAZtcfS-e-t28qP5xi43AQg_n1twcugoxcNtfWgB1n39j_-F7P_lZ0</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Chaulagain, Chakra P.</creator><creator>Diacovo, Julia M.</creator><creator>Elson, Leah</creator><creator>Comenzo, Raymond L.</creator><creator>Samaras, Christy</creator><creator>Anwer, Faiz</creator><creator>Khouri, Jack</creator><creator>Landau, Heather</creator><creator>Valent, Jason</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3152-1189</orcidid><orcidid>https://orcid.org/0000-0002-4641-2217</orcidid><orcidid>https://orcid.org/0000-0001-9169-3321</orcidid></search><sort><creationdate>20200301</creationdate><title>Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients</title><author>Chaulagain, Chakra P. ; Diacovo, Julia M. ; Elson, Leah ; Comenzo, Raymond L. ; Samaras, Christy ; Anwer, Faiz ; Khouri, Jack ; Landau, Heather ; Valent, Jason</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-efff9e68b38b5c94799798087d812d2b449561842c3688949f83e3381ffe93fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Amyloidosis</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Daratumumab</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Neoplasms, Plasma Cell - drug therapy</topic><topic>Organ Transplantation - methods</topic><topic>Plasmacytic post-transplant lymphoproliferative disorder</topic><topic>Solid organ transplant</topic><topic>Transplant Recipients - statistics & numerical data</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chaulagain, Chakra P.</creatorcontrib><creatorcontrib>Diacovo, Julia M.</creatorcontrib><creatorcontrib>Elson, Leah</creatorcontrib><creatorcontrib>Comenzo, Raymond L.</creatorcontrib><creatorcontrib>Samaras, Christy</creatorcontrib><creatorcontrib>Anwer, Faiz</creatorcontrib><creatorcontrib>Khouri, Jack</creatorcontrib><creatorcontrib>Landau, Heather</creatorcontrib><creatorcontrib>Valent, Jason</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chaulagain, Chakra P.</au><au>Diacovo, Julia M.</au><au>Elson, Leah</au><au>Comenzo, Raymond L.</au><au>Samaras, Christy</au><au>Anwer, Faiz</au><au>Khouri, Jack</au><au>Landau, Heather</au><au>Valent, Jason</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients</atitle><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><date>2020-03-01</date><risdate>2020</risdate><volume>20</volume><issue>3</issue><spage>e137</spage><epage>e143</epage><pages>e137-e143</pages><issn>2152-2650</issn><eissn>2152-2669</eissn><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32029395</pmid><doi>10.1016/j.clml.2019.12.022</doi><orcidid>https://orcid.org/0000-0002-3152-1189</orcidid><orcidid>https://orcid.org/0000-0002-4641-2217</orcidid><orcidid>https://orcid.org/0000-0001-9169-3321</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2152-2650 |
| ispartof | Clinical lymphoma, myeloma and leukemia, 2020-03, Vol.20 (3), p.e137-e143 |
| issn | 2152-2650 2152-2669 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8183688 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Amyloidosis Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Daratumumab Humans Male Middle Aged Multiple myeloma Neoplasms, Plasma Cell - drug therapy Organ Transplantation - methods Plasmacytic post-transplant lymphoproliferative disorder Solid organ transplant Transplant Recipients - statistics & numerical data |
| title | Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T21%3A41%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Daratumumab-based%20Regimen%20in%20Treating%20Clonal%20Plasma%20Cell%20Neoplasms%20in%20Solid%20Organ%20Transplant%20Recipients&rft.jtitle=Clinical%20lymphoma,%20myeloma%20and%20leukemia&rft.au=Chaulagain,%20Chakra%20P.&rft.date=2020-03-01&rft.volume=20&rft.issue=3&rft.spage=e137&rft.epage=e143&rft.pages=e137-e143&rft.issn=2152-2650&rft.eissn=2152-2669&rft_id=info:doi/10.1016/j.clml.2019.12.022&rft_dat=%3Cpubmed_cross%3E32029395%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32029395&rft_els_id=S2152265020300070&rfr_iscdi=true |